Coverage / GHRS / Trade Card

GHRS

GH Research PLC

OPPORTUNISTIC BUY Analysis generated 2026-10-28 Market data as of 2026-11-12 Market data 3 days old USD 18.49 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
USD 18.49
Buy <=wait / entry
USD 16.03
Trim >=take some off
USD 24.00
Thesis breakAn adverse FDA response for GH001, pivotal evidence showing clinically inadequat...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Presentation of GH001-TRD-201 and GH001-BD-202 trial data at ECNP 2026
  • Q2 2026 earnings report showing $15.1M loss and $362.7M cash position
  • Completion of $117.5M underwritten offering
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n